Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Phase II study to evaluate immunogenicity, reactogenicity and safety of GSK Biologicals’ investigational vaccination regimen compared to the currently licensed GSK Biologicals’ Priorix™ and Merck and Co.’s M-M-R®II vaccines when administered as a primary vaccination to healthy children aged 12-24 months
Measles, Mumps, Rubella Vaccine
209762/151
Measles; Mumps; Rubella
Phase 2
 
A two year follow-up study 104420 was conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2015

Powered by ideaPoint, Inc.